Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025GlobeNewsWire • 10/30/25
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155GlobeNewsWire • 10/29/25
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell TransplantGlobeNewsWire • 10/14/25
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash RunwayGlobeNewsWire • 09/23/25
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to BuyZacks Investment Research • 09/09/25
Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 08/28/25
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 08/27/25
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/06/25
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025GlobeNewsWire • 07/22/25
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual MeetingGlobeNewsWire • 05/27/25
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 05/23/25
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to TradeZacks Investment Research • 05/16/25
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/07/25
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune DiseasesGlobeNewsWire • 04/29/25
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025GlobeNewsWire • 04/23/25
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a TurnaroundZacks Investment Research • 04/17/25
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/13/25